|
1
|
Wiechmann L, Sampson M, Stempel M, Jacks
LM, Patil SM, King T and Morrow M: Presenting features of breast
cancer differ by molecular subtype. Ann Surg Oncol. 16:2705–2710.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Perou CM: Molecular stratification of
triple-negative breast cancers. Oncologist. 1 16 Suppl:S61–S70.
2011. View Article : Google Scholar
|
|
3
|
Perou CM, Sorlie T, Eisen MB, van de Rijn
M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA,
et al: Molecular portraits of human breast tumours. Nature.
406:747–752. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Abramson VG, Lehmann BD, Ballinger TJ and
Pietenpol JA: Subtyping of triple-negative breast cancer:
Implications for therapy. Cancer. 121:8–16. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Foulkes WD, Smith IE and Reis-Filho JS:
Triple-negative breast cancer. N Engl JMed. 363:1938–1948. 2010.
View Article : Google Scholar
|
|
6
|
Brenton JD, Carey LA, Ahmed AA and Caldas
C: Molecular classification and molecular forecasting of breast
cancer: Ready for clinical application? J Clin Oncol. 23:7350–7360.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Pignol JP, Rakovitch E and Olivotto IA: Is
breast conservation therapy superior to mastectomy for women with
triple-negative breast cancers? J Clin Oncol. 29:2841–2843. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Dent R, Trudeau M, Pritchard KI, Hanna WM,
Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P and Narod SA:
Triple-negative breast cancer: Clinical features and patterns of
recurrence. Clin Cancer Res. 13:4429–4434. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kyndi M, Sørensen FB, Knudsen H, Overgaard
M, Nielsen HM and Overgaard J; Danish Breast Cancer Cooperative
Group, : Estrogen receptor, progesterone receptor, HER-2, and
response to postmastectomy radiotherapy in high-risk breast cancer:
The danish breast cancer cooperative group. J Clin Oncol.
26:1419–1426. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Voduc KD, Cheang MC, Tyldesley S, Gelmon
K, Nielsen TO and Kennecke H: Breast cancer subtypes and the risk
of local and regional relapse. J Clin Oncol. 28:1684–1691. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gabos Z, Thoms J, Ghosh S, Hanson J,
Deschenes J, Sabri S and Abdulkarim B: The association between
biological subtype and locoregional recurrence in newly diagnosed
breast cancer. Breast Cancer Res Treat. 124:187–194. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
van Dongen JA, Voogd AC, Fentiman IS,
Legrand C, Sylvester RJ, Tong D, van der Schueren E, Helle PA, van
Zijl K and Bartelink H: Long-term results of a randomized trial
comparing breast-conserving therapy with mastectomy: European
organization for research and treatment of cancer 10801 trial. J
Natl Cancer Inst. 92:1143–1150. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Veronesi U, Cascinelli N, Mariani L, Greco
M, Saccozzi R, Luini A, Aguilar M and Marubini E: Twenty-year
follow-up of a randomized study comparing breast-conserving surgery
with radical mastectomy for early breast cancer. N Engl J Med.
347:1227–1232. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lazovich D, Solomon CC, Thomas DB, Moe RE
and White E: Breast conservation therapy in the United States
following the 1990 national institutes of health consensus
development conference on the treatment of patients with early
stage invasive breast carcinoma. Cancer. 86:628–637. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nguyen PL, Taghian AG, Katz MS, Niemierko
A, Abi Raad RF, Boon WL, Bellon JR, Wong JS, Smith BL and Harris
JR: Breast cancer subtype approximated by estrogen receptor,
progesterone receptor and HER-2 is associated with local and
distant recurrence after breast-conserving therapy. J Clin Oncol.
26:2373–2378. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Solin LJ, Hwang WT and Vapiwala N: Outcome
after breast conservation treatment with radiation for women with
triple-negative early-stage invasive breast carcinoma. Clin Breast
Cancer. 9:96–100. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Haffty BG, Yang Q, Reiss M, Kearney T,
Higgins SA, Weidhaas J, Harris L, Hait W and Toppmeyer D:
Locoregional relapse and distant metastasis in conservatively
managed triple negative early-stage breast cancer. J Clin Oncol.
24:5652–5657. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Millar EK, Graham PH, O'Toole SA, McNeil
CM, Browne L, Morey AL, Eggleton S, Beretov J, Theocharous C, Capp
A, et al: Prediction of local recurrence, distant metastases and
death after breast-conserving therapy in early-stage invasive
breast cancer using a five-biomarker panel. J Clin Oncol.
27:4701–4708. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gangi A, Chung A, Mirocha J, Liou DZ,
Leong T and Giuliano AE: Breast-conserving therapy for
triple-negative breast cancer. JAMA Surg. 149:252–258. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Connolly JL: Changes and problematic areas
in interpretation of the AJCC cancer staging manual, 6th edition,
for breast cancer. Arch Pathol Lab Med. 130:287–291.
2006.PubMed/NCBI
|
|
21
|
Elston CW and Ellis IO: Pathological
prognostic factors in breast cancer. I. The value of histological
grade in breast cancer: Experience from a large study with
long-term follow-up. Histopathology. 19:403–410. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tummaruk P, Tienthai P, Manee-In S and
Srisuwatanasagul S: Expression of progesterone receptor in the
utero-tubal junction after intra-uterine and deep intra-uterine
insemination in sows. Reprod Domest Anim. 45:e26–e31.
2010.PubMed/NCBI
|
|
23
|
Cejalvo JM, Martínez de Dueñas E, Galván
P, García-Recio S, Burgués Gasión O, Paré L, Antolín S, Martinello
R, Blancas I, Adamo B, et al: Intrinsic subtypes and gene
expression profiles in primary and metastatic breast cancer. Cancer
Res. 77:2213–2221. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kaplan HG, Malmgren JA and Atwood M: T1N0
triple negative breast cancer: Risk of recurrence and adjuvant
chemotherapy. Breast J. 15:454–460. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Noh JM, Choi DH, Huh SJ, Park W, Yang JH,
Nam SJ, Im YH and Ahn JS: Patterns of recurrence after
breast-conserving treatment for early stage breast cancer by
molecular subtype. J Breast Cancer. 14:46–51. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kim JY, Chang SK, Park H, Lee BM and Shin
HS: Treatment outcome in patients with triple negative early stage
breast cancers compared with other molecular subtypes. Radiat Oncol
J. 30:124–131. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Freedman GM, Anderson PR, Li T and
Nicolaou N: Locoregional recurrence of triple-negative breast
cancer after breast-conserving surgery and radiation. Cancer.
115:946–951. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Braunstein LZ, Niemierko A, Shenouda MN,
Truong L, Sadek BT, Abi Raad R, Wong JS, Punglia RS, Taghian AG and
Bellon JR: Outcome following local-regional recurrence in women
with early-stage breast cancer: Impact of biologic subtype. Breast
J. 21:161–167. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Abdulkarim BS, Cuartero J, Hanson J,
Deschenes J, Lesniak D and Sabri S: Increased risk of locoregional
recurrence for women with T1-2N0 triple-negative breast cancer
treated with modified radical mastectomy without adjuvant radiation
therapy compared with breast-conserving therapy. J Clin Oncol.
29:2852–2858. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang J, Shi M, Ling R, Xia Y, Luo S, Fu X,
Xiao F, Li J, Long X, Wang J, et al: Adjuvant chemotherapy and
radiotherapy in triple-negative breast carcinoma: A prospective
randomized controlled multi-center trial. Radiother Oncol.
100:200–204. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Guiu S, Michiels S, Andre F, Cortes J,
Denkert C, Di Leo A, Hennessy BT, Sorlie T, Sotiriou C, Turner N,
et al: Molecular subclasses of breast cancer: How do we define
them? The IMPAKT 2012 working group statement. Ann Oncol.
23:2997–3006. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Weigelt B, Mackay A, A'Hern R, Natrajan R,
Tan DS, Dowsett M, Ashworth A and Reis-Filho JS: Breast cancer
molecular profiling with single sample predictors: A retrospective
analysis. Lancet Oncol. 11:339–349. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lehmann BD, Bauer JA, Chen X, Sanders ME,
Chakravarthy AB, Shyr Y and Pietenpol JA: Identification of human
triple-negative breast cancer subtypes and preclinical models for
selection of targeted therapies. J Clin Invest. 121:2750–2767.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Eiermann W and Vallis KA: Locoregional
treatments for triple-negative breast cancer. Ann Oncol. 23 Suppl
6:vi30–vi34. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sotiriou C, Neo SY, McShane LM, Korn EL,
Long PM, Jazaeri A, Martiat P, Fox SB, Harris AL and Liu ET: Breast
cancer classification and prognosis based on gene expression
profiles from a population-based study. Proc Natl Acad Sci USA.
100:pp. 10393–10398. 2003; View Article : Google Scholar : PubMed/NCBI
|
